Healthcare ❯ Pharmaceuticals ❯ Drug Development

Oncology

Cancer Treatments Rare Diseases Bristol-Myers Squibb Company Venclexta Bristol Myers Squibb Zanidatamab Biosimilars Chronic Myeloid Leukemia Market Trends Nubeqa Basal Cell Carcinoma Alzheimer's Disease Incyte Cancer Drugs Immunology Clinical Trials Acquisitions HIV Therapies

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

The results signal a pivot to newer drugs with COVID sales fading.

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

J&J Beats Q4 Forecasts and Sets 2026 Guidance Above Wall Street

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Bristol Myers and J&J Cast as Dividend Plays as Bayer’s FXIa Win Refocuses Pipeline Interest

Morningstar Touts Bristol-Myers as a Top Deep-Value Pick Despite Patent Overhang

AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Boost In Vivo CAR-T Portfolio